Palbociclib

Palbociclib is an oral anticancer medicine belonging to the cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor class. These enzymes help regulate the cell cycle, particularly the transition from the G1 phase to the S phase, when a cell prepares to replicate its DNA. By inhibiting CDK4/6, palbociclib reduces phosphorylation of the retinoblastoma protein, helping prevent susceptible cancer cells from progressing through the cell cycle and multiplying. Its activity is particularly relevant in certain hormone receptor-positive breast cancers, in which signalling pathways involving cyclin D and CDK4/6 can contribute to tumour growth. Palbociclib is supplied as an oral medicine and is generally taken in repeated treatment cycles, with scheduled breaks to allow recovery from treatment-related bone marrow suppression. It is not ordinarily used alone for the approved breast cancer indications; instead, it is combined with appropriate endocrine therapy and, in certain specific settings, other targeted or anticancer treatments. The principal safety concern is neutropenia, a reduction in neutrophils that can increase the risk of infection. Complete blood counts and clinical assessment are therefore important throughout treatment. The choice of combination, dosing adjustments and duration depends on the cancer subtype, previous treatment, tolerance, laboratory findings and the applicable regulatory indication. Palbociclib should be prescribed and monitored by an oncology specialist.

Palbociclib was developed as a targeted therapy designed to inhibit CDK4/6-mediated cell-cycle progression. Its clinical development in advanced breast cancer included the PALOMA trial programme, which evaluated its use with endocrine therapies. The US Food and Drug Administration (FDA) granted initial approval in February 2015 for advanced breast cancer in combination with letrozole. The European Medicines Agency (EMA) recommended authorisation in September 2016, and the European Commission granted marketing authorisation on 9 November 2016. Subsequent regulatory changes expanded or refined its approved uses. In the United States, the FDA's April 2025 prescribing information included use with inavolisib and fulvestrant for selected adults with endocrine-resistant, PIK3CA-mutated, hormone receptor-positive and HER2-negative locally advanced or metastatic breast cancer following recurrence on or after completion of adjuvant endocrine therapy. On 24 June 2026, the FDA also approved palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy as maintenance treatment for adults with hormone receptor-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment. These newer indications are jurisdiction-specific and should not be assumed to be approved in every country. Regulatory status in India should be verified against current Central Drugs Standard Control Organisation (CDSCO) approvals and the locally authorised product information. Key clinical evidence includes the PALOMA trials and the PATINA trial for the newer HER2-positive maintenance indication.

Palbociclib is used for selected adults with advanced or metastatic breast cancer, with the approved indication determined by tumour biology, previous treatment and the treatment combination. Established uses include hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor, such as letrozole, as endocrine-based treatment, or with fulvestrant when disease has progressed following endocrine therapy. In premenopausal or perimenopausal women, appropriate ovarian suppression with a gonadotropin-releasing hormone agonist is generally required when indicated by the treatment regimen. In the United States, palbociclib is also approved with inavolisib and fulvestrant for a selected PIK3CA-mutated, endocrine-resistant, HR-positive and HER2-negative population. A further US indication covers maintenance treatment of HR-positive, HER2-positive advanced or metastatic breast cancer following induction therapy, in combination with trastuzumab, with or without pertuzumab, and endocrine therapy. The latter indication should not be generalised to all patients with HER2-positive disease or interpreted as a universal indication outside the United States. Palbociclib is not a general treatment for every type of breast cancer, and treatment selection requires confirmation of receptor status, relevant mutation testing where required, disease history and applicable local approval.

Palbociclib is administered orally as capsules or tablets, depending on the authorised formulation. The usual adult starting dose for many approved regimens is 125 mg once daily for 21 consecutive days, followed by seven days without palbociclib, completing a 28-day cycle. The dose and schedule of the accompanying endocrine or targeted therapies depend on the specific regimen. Patients should follow the instructions for their exact formulation: capsules and tablets may have different food-related administration instructions, and the directions for one formulation should not automatically be applied to another. Doses may need to be reduced or treatment temporarily interrupted for neutropenia, other adverse effects, liver abnormalities or drug interactions. Treatment is generally continued until disease progression or unacceptable toxicity, subject to the relevant indication and prescribing information. Complete blood counts should be checked before treatment, at the beginning of each cycle and during early cycles as directed by the prescribing information; additional assessments are necessary when clinically indicated. Patients should not change their dose, restart treatment after a significant interruption or compensate for a missed dose without advice from their oncology team.

Common adverse effects of palbociclib include neutropenia, reduced white blood cell counts, anaemia, fatigue, nausea, mouth soreness or inflammation, diarrhoea, decreased appetite, hair thinning, rash and infections. Some patients also experience reduced platelet counts, dry skin or changes in liver enzyme results. Neutropenia is particularly important because it may occur without obvious symptoms and can require a treatment interruption, dose reduction or closer blood-count monitoring. The severity and combination of side effects vary between patients and may be influenced by the accompanying medicines, other medical conditions and individual tolerance. Many adverse effects can be managed through supportive care, laboratory monitoring and clinician-directed dose adjustments. Patients should promptly report fever, chills, new respiratory symptoms, unusual bruising, persistent diarrhoea, worsening fatigue or other symptoms that are new, severe or persistent. Supportive treatment should be selected according to the patient's clinical circumstances rather than started independently.

The principal serious toxicity associated with palbociclib is neutropenia, which can lead to serious or life-threatening infections, including febrile neutropenia. Severe anaemia and thrombocytopenia may also occur. Rare but important respiratory risks include interstitial lung disease and pneumonitis; new or worsening breathlessness, cough or unexplained respiratory symptoms require prompt assessment. Liver abnormalities and severe hypersensitivity reactions are additional concerns. Palbociclib can cause fetal harm based on its mechanism of action and nonclinical findings; pregnancy should be avoided during treatment, and effective contraception and pregnancy-related counselling are required in accordance with the applicable prescribing information. Breastfeeding should be avoided during treatment and for the recommended period after the final dose specified in the local product information. Treatment may need to be withheld, reduced or discontinued for severe or recurrent toxicity, serious infection, suspected drug-induced lung injury or other clinically significant adverse events. There is no single universal contraindication list for every jurisdiction and formulation, so the current local prescribing information must be consulted before treatment.

Before starting palbociclib, clinicians should assess the complete blood count, liver function, infection history, pregnancy status where relevant and the patient's overall clinical condition. Tumour receptor status and any required molecular testing should be confirmed to establish eligibility for the intended combination. Palbociclib is primarily metabolised by CYP3A enzymes; strong CYP3A inhibitors can increase exposure and toxicity, whereas strong CYP3A inducers can reduce exposure and potentially compromise efficacy. Examples of medicines that may require particular attention include certain azole antifungals, macrolide antibiotics, anticonvulsants and rifamycin antibiotics. Grapefruit and grapefruit juice may also affect CYP3A activity and should be avoided according to product instructions. Medication reconciliation should include prescription medicines, non-prescription products and herbal preparations. Unlike many biologic medicines, palbociclib has clinically important conventional metabolic drug interactions. Patients should inform their healthcare team about all medicines and supplements they take. Live vaccines may be unsuitable during treatment, particularly in the presence of significant immunosuppression; vaccination timing and the use of non-live vaccines should be reviewed by the treating team. Particular care is required in patients with hepatic impairment, recurrent infections, pre-existing lung disease or other conditions that may complicate toxicity monitoring.

Prescribers and pharmacists should verify the exact indication, tumour receptor profile, required mutation results and locally approved combination before dispensing palbociclib. Confirm the formulation, strength, cycle schedule and administration instructions, as capsule and tablet instructions may differ. Obtain a baseline complete blood count and liver function tests, then arrange blood-count monitoring at the intervals specified in the applicable prescribing information, with particular attention to the first two cycles and any previous episodes of neutropenia. Review CYP3A-mediated interactions before treatment and whenever another medicine is started, stopped or changed. Counsel patients to recognise fever and infection symptoms, report respiratory symptoms promptly, avoid grapefruit where specified and follow pregnancy-prevention and breastfeeding guidance. Reinforce adherence to the planned 21-days-on, seven-days-off schedule when that regimen is prescribed; patients should not double a missed dose or take extra doses after vomiting. Document treatment interruptions, dose reductions and laboratory trends clearly. In combination regimens, coordinate monitoring and toxicity management across oncology, pharmacy and supportive-care teams. Report suspected serious adverse reactions through the applicable national pharmacovigilance system.